Nicotinic Acids

2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin.

Also Known As:

Networked: 13 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Masuda, Daisaku: 1 article (01/2020)
2.	Matsuzawa, Yuji: 1 article (01/2020)
3.	Yamashita, Shizuya: 1 article (01/2020)
4.	Hanefeld, Markolf: 1 article (05/2011)
5.	Stahn, Annett: 1 article (05/2011)
6.	Alemao, Evo: 1 article (05/2007)
7.	Cook, John R: 1 article (05/2007)
8.	Davies, Glenn M: 1 article (05/2007)
9.	Gould, A Lawrence: 1 article (05/2007)
10.	Yin, Donald D: 1 article (05/2007)

Related Diseases

1.	Myocardial Infarction 05/01/2007 - "Using a literature search (MeSH key terms, including: bezafibrate, coronary disease, efficacy, gemfibrozil, hydroxymethylglutaryl-CoA reductase inhibitors, hypercholesterolemia, niacin [nicotinic acids], randomized controlled trials, and treatment outcome; years: 1999-2005), we identified trials published in English that assessed the effects of lipid-modifying therapies on CHD end points, including CHD-related death, myocardial infarction, and angina pectoris. "
2.	Hypercholesterolemia 05/01/2007 - "Using a literature search (MeSH key terms, including: bezafibrate, coronary disease, efficacy, gemfibrozil, hydroxymethylglutaryl-CoA reductase inhibitors, hypercholesterolemia, niacin [nicotinic acids], randomized controlled trials, and treatment outcome; years: 1999-2005), we identified trials published in English that assessed the effects of lipid-modifying therapies on CHD end points, including CHD-related death, myocardial infarction, and angina pectoris. "
3.	Coronary Disease (Coronary Heart Disease) 05/01/2007 - "Using a literature search (MeSH key terms, including: bezafibrate, coronary disease, efficacy, gemfibrozil, hydroxymethylglutaryl-CoA reductase inhibitors, hypercholesterolemia, niacin [nicotinic acids], randomized controlled trials, and treatment outcome; years: 1999-2005), we identified trials published in English that assessed the effects of lipid-modifying therapies on CHD end points, including CHD-related death, myocardial infarction, and angina pectoris. "
4.	Angina Pectoris 05/01/2007 - "Using a literature search (MeSH key terms, including: bezafibrate, coronary disease, efficacy, gemfibrozil, hydroxymethylglutaryl-CoA reductase inhibitors, hypercholesterolemia, niacin [nicotinic acids], randomized controlled trials, and treatment outcome; years: 1999-2005), we identified trials published in English that assessed the effects of lipid-modifying therapies on CHD end points, including CHD-related death, myocardial infarction, and angina pectoris. "
5.	Hypertriglyceridemia 05/02/2023 - "Hypertriglyceridemia and/or low HDL-C can be treated with fibrates, nicotinic acids, and n-3 polyunsaturated fatty acids. " 01/01/2020 - "To treat patients with hypertriglyceridemia and/or low HDL-C, drugs such as fibrates, nicotinic acids, and n-3 polyunsaturated fatty acids have been used. " 01/01/2001 - "Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids. "

Related Drugs and Biologics

1.	Lipids
2.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
3.	Gemfibrozil (Lopid)
4.	Niacin (Nicotinic Acid)
5.	Bezafibrate
6.	Fibric Acids (Fibrates)
7.	Niacinamide (Nicotinamide)
8.	Quinolinic Acid
9.	Sulfates (Sulfates, Inorganic)
10.	Kynurenine

Related Therapies and Procedures

1.	Therapeutics